Snapshot from Aug 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Natera Submits Signatera to Japan PMDA
Regulatory regulatory submission

Natera Submits Signatera to Japan PMDA

Analysis based on 7 articles · First reported Aug 05, 2026 · Last updated Aug 05, 2026

Sentiment
30
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The submission expands Natera's regulatory footprint in Japan, a key market for its Signatera test, potentially driving future revenue growth. Positive trial data and prior approvals strengthen Natera's competitive position in the MRD diagnostics market, likely supporting its stock price.

Biotechnology Diagnostics Oncology
Event Summary

Natera announced that it has submitted an application to Japan's Japan — Pharmaceuticals and Medical Devices Agency (PMDA) for approval of its Signatera test as a companion diagnostic (CDx) in muscle-invasive bladder cancer (MIBC). The submission is supported by data from the IMvigor011 Phase 3 trial, which showed that patients receiving adjuvant atezolizumab (Tecentriq) had nearly double the disease-free survival compared to placebo (9.9 vs 4.8 months) and improved overall survival. This follows the PMDA's approval of Signatera in colorectal cancer in June, making it the first PMDA-approved molecular residual disease (MRD) test in Japan. The MIBC application also builds on recent milestones including the U.S. FDA's approval of Signatera as a companion diagnostic for adjuvant atezolizumab and a Category 1 recommendation from the National Comprehensive Cancer Network (NCCN) for Signatera MRD-guided adjuvant atezolizumab in bladder cancer guidelines. Natera's shares rose slightly in pre-market trading following the announcement.

Key Actions
100 Natera submitted application Japan — Pharmaceuticals and Medical Devices Agency
80 United States — Food and Drug Administration approved Natera
70 National Comprehensive Cancer Network included Natera
Entities Involved
stock
Natera
Natera is the applicant and primary beneficiary, seeking PMDA approval to expand Signatera's use in Japan. The submission follows recent FDA and NCCN endorsements, reinforcing its leadership in MRD testing.
Importance 100.0 Sentiment 40.0
govactor
Japan — Pharmaceuticals and Medical Devices Agency
The PMDA is the regulatory authority reviewing Natera's application. Its decision will determine market access for Signatera in MIBC in Japan.
Importance 80.0 Sentiment 0.0
subs
F. Hoffmann-La Roche — Genentech
F. Hoffmann-La Roche — Genentech's Tecentriq (atezolizumab) is the therapy guided by Signatera in this CDx application. Positive trial data could boost Tecentriq's use in adjuvant bladder cancer.
Importance 70.0 Sentiment 20.0
cnt
Japan
Japan is the target market, with over 34,000 bladder cancer cases annually. Approval would provide Japanese patients access to a novel MRD-guided therapy approach.
Importance 60.0 Sentiment 10.0
stock
Roche
Roche, parent of F. Hoffmann-La Roche — Genentech, stands to benefit from expanded use of Tecentriq in MIBC, potentially increasing drug sales.
Importance 50.0 Sentiment 15.0
govactor
United States — Food and Drug Administration
The FDA previously approved Signatera as a companion diagnostic for adjuvant Tecentriq, providing a regulatory precedent that supports the Japan submission.
Importance 40.0 Sentiment 0.0
ngo
National Comprehensive Cancer Network
The NCCN's Category 1 recommendation for Signatera MRD-guided adjuvant atezolizumab in bladder cancer guidelines adds clinical credibility and may influence adoption.
Importance 30.0 Sentiment 0.0
per
Alexey Aleshin
Alexey Aleshin, Natera's chief medical officer, is the spokesperson for the submission, representing the company's commitment to expanding precision diagnostics in Japan.
Importance 20.0 Sentiment 0.0
Relationships
F. Hoffmann-La Roche — Genentech related ↔ Roche
Japan related ↔ Roche
Japan related ↔ United States — Food and Drug Administration
Roche related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.